רנוולה טבליות 800 מג
sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.
רנוולה אבקה 2.4 גרם
sanofi israel ltd - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g/sachet - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney diseasenot on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.
סבלמר תרו 800 מג
taro international ltd, israel - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer
סבלמר תרו 800 מג
taro international ltd, israel - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer
סבלמר תרו 2.4 ג'
taro international ltd, israel - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g - sevelamer
רנג'ל טבליות 800 מ"ג
sanofi - aventis israel ltd - sevelamer hydrochloride 800 mg - film coated tablets - sevelamer - reduction of serum phosphorus in patients with end stage renal disease ( esrd) . the safety and efficacy of renagel in esrd patients who are not on hemodialysis have not been studied. in hemodialysis patients renagel decreases the incidence of hypercalcemic episodes relative to patients on calcium acetate treatment.
פוסרנול 500 מג טבליות לעיסה
takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 500 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
פוסרנול 750 מג טבליות לעיסה
takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
פוסרנול 1000 מג בליות לעיסה
takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
וולפורו
cts ltd - iron as sucroferric oxyhydroxide - טבליות לעיסות - iron as sucroferric oxyhydroxide 500 mg - sucroferric oxyhydroxide